Xylem (XYL) Tops Q3 EPS by 13c; Raises FY EPS Outlook

Xylem (NYSE: XYL) reported Q3 EPS of $0.79, $0.13 better than the analyst estimate of $0.66. Revenue for the quarter came in at $1.4 billion versus the consensus estimate of $1.34 billion.

GUIDANCE:

Xylem sees FY2022 EPS of $2.65-$2.75, versus prior of $2.50-$2.70 and the consensus of $2.60.

For earnings history and earnings-related data on Xylem (XYL) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Hydrofarm Holdings Group, Inc. (HYFM) Misses Q2 EPS by 134c
• Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c